Caricamento...
First Reported Case of Hemopericardium Related to Dabigatran Use Reversed by New Antidote Idarucizumab
Dabigatran, the first novel oral anticoagulant (NOAC) with a reversal agent, heralded a paradigm shift in the treatment of nonvalvular atrial fibrillation. The potential for life-threatening hemorrhagic events with the use of NOACs has been highly debated since the effectiveness of reversal agents s...
Salvato in:
| Pubblicato in: | Case Rep Cardiol |
|---|---|
| Autori principali: | , , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Hindawi
2017
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5488311/ https://ncbi.nlm.nih.gov/pubmed/28695019 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2017/6458636 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|